

بِسْمِ اللّٰهِ الرَّحْمٰنِ الرَّحِیْمِ





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار






بعض الوثائق الأصلية تالفة





بالرسالة صفحات لم ترد بالأصل



***“Study on the effect of Deferiprone on
Scopolamine-induced memory deficit in rats”***

A thesis submitted in the partial fulfilment of requirements for the
master’s degree in Pharmaceutical Sciences
(Pharmacology & Toxicology)

By:

Sylvia Fransis Fawzy Attallah

Teaching assistant of Pharmacology and Toxicology, Faculty of
Pharmacy, Badr University in Cairo, BUC

Under the supervision of:

Professor Mariane George Tadros

Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain
Shams University

Associate Professor Esther Tharwat Menze

Associate Professor of Pharmacology and Toxicology, Faculty of
Pharmacy, Ain Shams University

Department of Pharmacology and Toxicology
Faculty of Pharmacy, Ain Shams University

(2020)

Acknowledgement

First and above all; utmost thanks and glory to Almighty God for the divine intervention in my whole life.

I wish to thank, first and foremost, Doctor Mariane George, Professor of Pharmacology and Toxicology, for her great support, unwavering guidance and continuous encouragement and for her generosity in sharing her tremendously valuable expertise.

I am heartily thankful to Doctor Esther Tharwat Menze, Associate Professor of Pharmacology and Toxicology Faculty of Pharmacy Ain Shams University, for her direct supervision, precious advices and inspiration and for saving no effort in helping me.

I also wish to thank my Professors; Prof. Mohamed El-Shanawany, Dean of Faculty of Pharmacy, BUC and Prof. Safaa El-Moghazy, Vice dean of Faculty of Pharmacy, BUC for their continuous support.

I would like to thank my friends and colleagues from the department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for their support and for sharing their knowledge and experiences, especially, Mina Youssef George.

It also should be mentioned that this thesis would not have been possible without the unwavering emotional and financial support of my husband, and my entire family.

Finally, I offer my regards and blessings to all of those who supported me in any aspect during the completion of the project.

Index

Abstract	XI
I. Introduction.....	- 1 -
1. Dementia.....	- 1 -
1.1. Definition.....	- 1 -
1.2. History of Diagnosis.....	- 1 -
1.3. Prevalence.....	- 2 -
1.4. Etiology	- 3 -
1.5. Classification of Dementia	- 4 -
2. Alzheimer's disease	- 9 -
2.1. Definition.....	- 9 -
2.2. History.....	- 10 -
2.3. Epidemiology.....	- 11 -
2.4. Signs and Symptoms	- 11 -
1.6. Alzheimer's Pathophysiology.....	- 15 -
1.7. Current Treatment Strategies of Alzheimer's Disease.....	- 26 -
3. Chelation Therapy.....	- 32 -
3.1. Chelation Therapy in Treatment of Alzheimer's Disease	- 32 -
3.2. The Risk of Chelation Therapy.....	- 34 -
4. Deferiprone	- 38 -
4.1. Deferiprone Structure.....	- 38 -
4.2. Deferiprone As a Chelating Agent.	- 38 -
4.3. Pharmacokinetics	- 39 -
4.4. Pharmacological Actions	- 40 -
II. Aim of work	- 45 -
III. Materials and Methods	- 47 -
1. Experimental Design.....	- 47 -
2. Animals	- 51 -
3. Materials	- 51 -
3.1. Drugs.....	- 51 -
3.2. Chemicals and Reagents	- 52 -
3.3. Buffers	- 53 -

Index

3.4. kits	- 55 -
3.4. Apparatuses	- 57 -
4. Methods.....	- 60 -
4.1. Behavioural Experiments	- 60 -
4.2. Biomarkers of Oxidative Stress	- 62 -
4.3. Acetylcholinesterase Activity.....	- 69 -
4.4. Histopathological Examination.....	- 72 -
4.5. β -Amyloid Disposition by Congo red staining	- 73 -
4.6. Iron Disposition Detection by Prussian Blue Staining of Brain Tissue..	- 74 -
5. Statistical Analysis.....	- 75 -
IV. Results.....	- 76 -
1. Behavioural Experiments.....	- 76 -
1.1. Morris Water Maze Test.....	- 76 -
1.2. Step-through Passive Avoidance Test	- 82 -
2. Effects of Deferiprone on Hippocampal and Cortical Oxidative Stress Biomarkers.....	- 85 -
2.1. Catalase Activity.....	- 85 -
2.2. Reduced Glutathione Levels.....	- 88 -
2.3. Malondialdehyde Levels.....	- 91 -
3. Hippocampal and Cortical Acetylcholinesterase Activity	- 94 -
4. Histopathological Examination of the Hippocampal and Cortical Tissues by H&E Staining	- 97 -
5. Histopathological Examination of β-Amyloid Disposition in Different Areas of the Brain by Congo Red Staining	- 103 -
6. Histopathological Examination of Iron Disposition in Different Areas of the Brain by Prussian Blue Staining	- 105 -
V. Discussion.....	- 108 -
VI. Summary and Conclusion	- 118 -
VII. References	- 125 -

List of Abbreviations

AAP	4-Aminoantipyrine
Ach	Acetylcholine
AChE	Acetylcholinesterase
AD	Alzheimer's disease
Al	Aluminium
ANOVA	Analysis of variance
APP	Amyloid protein precursor
A_{Sample}	Sample absorbance
A_{Standard}	Standard absorbance
ATCh	Acetylthiocholine
ATChI	Acetylthiocholine iodide
ATP	Adenosine triphosphate
AUC	Area under the curve
$A\beta$	Amyloid- β protein
BACE1	Beta-site APP cleaving enzyme-1
CA1	Subfield of the hippocampus
CA3	Subfield of the hippocampus
C_{max}	Peak plasma concentration
Cu	Copper
DFO	Deferroxamine
DFP	Deferiprone
DG	Dentate Gyrus region
DHBS	3, 5-Dichloro -2-hydroxybenzene sulfonic acid
DLB	Dementia with Lewy Bodies
DTNB	Dithiobisnitrobenzoic acid
E	Edema
Fe^{2+}	Ferrous ion

List of Abbreviations

Fe ³⁺	Ferric ion
FeNTA	Ferric nitrilotriacetate
FTD	Fronto-temporal dementia
G	Glial cell infiltration
GSH	Reduced Glutathione
H&E	Hematoxylin and eosin stain
H ₂ O ₂	Hydrogen peroxide
i.p	Intra-peritoneal
MCI	Mild cognitive impairment
NaHCO ₃	Sodium bicarbonate
NMDA	N-methyl-D-aspartate
NSAIDs	Nonsteroidal anti-inflammatory drugs
OD	Optical Density
p.o	Oral
PD	Parkinson's disease
PET	Positron emission tomography
R	Reagent
ROS	Reactive oxygen species
rpm	Rotation per minute
SCOP	Scopolamine
SEM	Standard error of the mean
t _{1/2}	Elimination half-life
TBA	Thiobarbituric acid
TBARS	Thiobarbituric acid reactive species
USA	United states of America
UV	Ultra-violet
VaD	Vascular dementia

List of Abbreviations

VN	Vesicular nuclei
WHO	World Health Organization
Zn	Zinc
β A4	β -amyloid peptide 4

List of Figures

Figure no.	Title	Page
Figure 1	<i>Estimate of numbers of people living with dementia worldwide.</i>	- 3 -
Figure 2	<i>Amyloid Cascade Hypothesis</i>	- 22 -
Figure 3	<i>The non-amyloidogenic and amyloidogenic pathways of Amyloid precursor protein</i>	- 24 -
Figure 4	<i>Role of chelators in disposition of β-amyloid plaques</i>	- 37 -
Figure 5	<i>Chemical structure of Deferiprone</i>	- 38 -
Figure 6	<i>Deferiprone and its chelation with iron</i>	- 38 -
Figure 7	<i>Experimental Diagram</i>	- 50 -
Figure 8	<i>Morris water maze apparatus</i>	- 57 -
Figure 9	<i>Step-through passive avoidance apparatus</i>	- 58 -
Figure 10	<i>Effect of Scopolamine and/or Deferiprone on the latency time during Morris water maze training</i>	- 79 -
Figure 11	<i>Effect of Deferiprone on time spent in platform quadrant (Probe test) on Scopolamine-treated rats</i>	- 81 -
Figure 12	<i>Effect of Scopolamine and/or Deferiprone on step-through latency of passive avoidance task</i>	- 84 -
Figure 13	<i>Effects of Deferiprone on the hippocampal and cortical catalase activities of Scopolamine-treated rats</i>	- 87 -

List of Figures

Figure 14	<i>Effects of Deferiprone on the hippocampal and cortical GSH levels of Scopolamine-treated rats</i>	- 90 -
Figure 15	<i>Effects of Scopolamine and/or Deferiprone on hippocampal and cortical Malondialdehyde levels in rats</i>	- 93 -
Figure 16	<i>Effects of Scopolamine and/or Deferiprone on hippocampal and cortical Acetylcholinesterase activity of rats</i>	- 96 -
Figure 17	<i>H&E staining of CA1 region of the hippocampi</i>	- 99 -
Figure 18	<i>H&E staining of CA3 region of the hippocampi</i>	- 100 -
Figure 19	<i>H&E staining of dentate gyrus region of the hippocampi</i>	- 101 -
Figure 20	<i>H&E staining of outer cortical layers of rat brains</i>	- 102 -
Figure 21	<i>Congo red staining of β-amyloid</i>	- 104 -
Figure 22	<i>Prussian blue staining of iron</i>	- 106 -

List of Tables

Table no.	Title	Page
Table 1	<i>Experimental Groups</i>	- 48 -
Table 2	<i>Effect of Scopolamine and/or Deferiprone on the latency time during Morris water maze training</i>	- 78 -
Table 3	<i>Effect of Deferiprone on time spent in platform quadrant in Scopolamine-treated rats</i>	- 80 -
Table 4	<i>Effect of Scopolamine and/or Deferiprone on step-through latency of passive avoidance task</i>	- 83 -
Table 5	<i>Effects of Deferiprone on the hippocampal and cortical catalase activities of Scopolamine-treated rats</i>	- 86 -
Table 6	<i>Effects of Deferiprone on the hippocampal and cortical glutathione levels of Scopolamine-treated rats</i>	- 89 -
Table 7	<i>Effects of Scopolamine and/or Deferiprone on hippocampal and cortical malondialdehyde levels in rats</i>	- 92 -
Table 8	<i>Effects of Scopolamine and/or Deferiprone on hippocampal and cortical Acetylcholinesterase activity of rats</i>	- 95 -
